Calls Now Open
2022 ADDF-Harrington and 2023 Harrington UK Rare Disease Programs
October 11, 2021
Metabolic syndrome is a cluster of conditions and includes obesity and can be dangerous as it increases the risk for heart disease, stroke, diabetes and other diseases. A Harrington Discovery Institute research team proves successful use of “anti-obesity” drug in pre-clinical animal models.
“The last piece of the puzzle is to develop clinical-grade anti-asprosin monoclonal antibodies in readiness for human trials. This requires a series of steps and culminates in an Investigational New Drug (IND) application to the FDA. We are well on our way down that path and look forward to completing this journey with anticipation.”
- Atul Chopra, MD, PhD
University Hospitals - Cleveland
2018 Harrington Investigators